Patient characteristics*
| Derivation cohort | Validation cohort | |
|---|---|---|
| (n=405) | (n=296) | |
| Age (years), median (IQR) | 48 (42–56) | 55 (48–61) |
| Men | 275/405 (68) | 162/296 (55) |
| BMI (kg/m2), median (IQR)† | 26.5 (24.0–29.5) | – |
| Stage of liver disease | ||
| Bridging fibrosis | 105/405 (26) | 0 (0) |
| Cirrhosis | 300/405 (74) | 296 (100) |
| HCV genotype | ||
| 1 | 290/384 (76) | 169/230 (74) |
| 2 | 21/384 (5) | 49/230 (21) |
| 3 | 52/384 (14) | 10/230 (4) |
| 4 | 18/384 (5) | 1/230 (0) |
| Other | 3/384 (<1) | 1/230 (0) |
| Diabetes mellitus | 55/405 (14) | – |
| History of alcohol use‡ | ||
| No | – | 196/296 (66) |
| Any | – | 100/296 (34) |
| Severe | 88/374 (24) | – |
| AntiHBc positivity | 153/325 (47) | 96/275 (35) |
| Laboratory data, median (IQR)§ | ||
| Platelet count (×109/L) | 145 (109–195) | 132 (99–173) |
| Albumin (g/L) | 42 (39–44) | 42 (38–45) |
| Bilirubin (μmol/L) | 14 (10–19) | 15 (12–20) |
| AST/ALT ratio | 0.71 (0.58–0.91) | 0.72 (0.56–0.92) |
*Data are presented as no./total no. (%) unless otherwise noted.
†Baseline BMI was missing in 113 (28%) patients in the derivation cohort and was not available in the validation cohort.
‡In the derivation cohort patients were classified as having a history of severe alcohol use (the use of more than 50 g of alcohol a day) or not. In the validation, patients were classified as having a history of using any alcohol or not.
§In the derivation and validation cohorts, baseline platelet count was missing in 68 (17%) patients and 0 (0%) patients, albumin in 100 (25%) and 30 (10%), bilirubin in 81 (20%) and 13 (4%), and AST/ALT ratio in 90 (22%) and 0 (0%), respectively.
ALT, alanine aminotransferase; antiHBc, anti-hepatitis B core antigen; AST, aspartate aminotransferase; BMI, body mass index; HCV, hepatitis C virus.